LBIO Stock UPDATES Lion Biotechnologies Inc. (LBIO) 7.2500 09/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lion Biotechnologies Inc. (LBIO) 7.2500 $LBIO

Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.

Lion Biotechnologies Names Elma Hawkins President and Chief Operating Officer
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has hired Elma Hawkins, PhD, MBA, to serve as president and chief operating officer. Her appointment is effective immediately.

Lion Biotechnologies' Chief Scientific Officer to Present at Immunotherapies and Vaccines Summit
GlobeNewswire - Mon Aug 11, 7:02AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Laszlo Radvanyi, PhD, the company's chief scientific officer (CSO), will present at the ninth annual Immunotherapies and Vaccines Summit (ImVacS), to be held August 11-14 in Boston, MA.

Lion Biotechnologies Enters Clinical Trial Grant Agreement With Moffitt Cancer Center
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a clinical trial grant agreement with Moffitt Cancer Center to expand an ongoing Phase 1 study of TILs combined with ipilimumab in patients with metastatic melanoma.

Lion Biotechnologies Announces Exclusive License Agreement With Moffitt Cancer Center
GlobeNewswire - Fri Jul 25, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into an exclusive, worldwide license agreement with Moffitt Cancer Center.

Lion Biotechnologies Leases New Research Laboratory
GlobeNewswire - Wed Jul 23, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a five-year lease agreement for a new research laboratory at University of South Florida Research Park in Tampa, FL.

Lion Biotechnologies Appoints Dr. Laszlo Radvanyi as Chief Scientific Officer
GlobeNewswire - Mon Jun 23, 7:01AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has appointed Laszlo Radvanyi, PhD, as its chief scientific officer (CSO).

Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.

Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.

Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.

Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.

Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.

Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered

Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.

Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 274

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 252

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
ss="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles